| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.065 | 0.04 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.071 | 0.04 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.04 |
| mRNA | leptomycin B | CTRPv2 | pan-cancer | AAC | 0.072 | 0.04 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.04 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.04 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.04 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | -0.079 | 0.05 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.077 | 0.05 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.074 | 0.05 |